Peptides for weight loss for women: what midlife women are using, and how much evidence sits behind each

Scroll any women’s health feed in 2026 and “peptides for weight loss” shows up as one category: a GLP-1 shot, a MOTS-c vial, a 5-Amino-1MQ tablet, sometimes all three in one routine. They do not belong in one category. Some have been tested in thousands of women; others have been tested in a few dozen mice, most of them male. This guide sorts what midlife women are actually using by how much evidence sits behind each, and asks a question most coverage skips: were women ever studied? Every research statement links to its primary source, and the community section is kept separate from the evidence.

What peptides do women use for weight loss?

Women in midlife use two very different groups of products under the “peptide” label. The first is approved peptide drugs: semaglutide (Wegovy) and tirzepatide (Zepbound), both FDA-approved for chronic weight management (Wegovy prescribing information, DailyMed; Zepbound prescribing information, DailyMed). They mimic gut hormones that regulate appetite and fullness.

The second is research compounds sold online in the same “weight loss” categories: MOTS-c, a peptide made by mitochondria; 5-Amino-1MQ, a small molecule that is not a peptide at all; and tesamorelin, an approved drug for a narrow HIV-related use that is discussed off-label for belly fat. Our sister site’s guide to peptides for weight loss covers the full category, including investigational retatrutide. This page asks what each one means for women specifically.

Peptides for weight loss for women, side by side

The table ranks the options by the strength of their human weight-loss evidence and adds the column that matters most here: whether women were in the studies. Sources are linked in the sections below.

The pattern is plain: the options with the most evidence are also the ones tested in women, and the trending research compounds have the least of both.

Why weight and body composition change in perimenopause and menopause

The fall in estrogen during the menopausal transition, not a failure of willpower, is closely tied to the weight redistribution women notice in midlife. As estrogen declines, fat that used to sit under the skin migrates to the abdomen as visceral fat around the organs. On average, visceral fat rises from roughly 5–8% of total body fat before menopause to about 15–20% after it, and one study measured visceral fat climbing about 8% a year in the two years before the final menstrual period and about 6% a year after it (contemporary review, PMC).

Lower estrogen is also associated with a drop in lean body mass alongside the rise in fat mass, and aging itself is associated with a decline in resting metabolic rate and total energy expenditure (contemporary review, PMC). That review ties the fall in metabolic rate to chronological aging rather than to estrogen loss specifically, so midlife weight change is best understood as menopause and aging acting together. The shift toward visceral fat and away from muscle is the pattern linked to higher cardiovascular and metabolic risk, which is why the goal in midlife is protecting muscle and reducing visceral fat, not just a smaller number on the scale.

Are peptides the same as Ozempic?

Ozempic is a peptide drug, but most products sold as “peptides” are not Ozempic. Ozempic’s active ingredient, semaglutide, is a GLP-1 receptor agonist approved for type 2 diabetes (Ozempic prescribing information, DailyMed); Wegovy is the same molecule approved for weight management (Wegovy prescribing information). MOTS-c and 5-Amino-1MQ work through different pathways and have never been through the human trials semaglutide passed. The word “peptide” alone tells you nothing about how much evidence sits behind a product.

Do GLP-1s work for women in menopause?

Yes. GLP-1 medications produce substantial weight loss in perimenopausal and postmenopausal women, comparable to what younger women see. Women were the majority in the pivotal trials: in the Wegovy label’s main adult weight-reduction study, 74% of participants were female (Wegovy prescribing information), and in Zepbound’s main trial in adults without diabetes, 68% were female (Zepbound prescribing information).

A secondary analysis of the SURMOUNT program covering 2,542 women looked at menopause directly. In SURMOUNT-1, perimenopausal and postmenopausal women lost about 23% of body weight on tirzepatide versus roughly 3% on placebo, close to the 26% seen in premenopausal women, with large reductions in waist circumference (NewYork-Presbyterian / Weill Cornell summary). Across the subgroups, 97% to 98% of women on tirzepatide lost at least 5% of their weight, against 29% to 33% on placebo (Tchang et al., Obesity 2025, PMC).

The caveat belongs in plain sight. The original trials did not record reproductive stage, so the authors sorted women into stages after the fact using age, lab values and history, and they describe the analysis as exploratory (Tchang et al., 2025). The result is strong, but menopause-specific evidence still comes from subgroup analyses, not trials built for the question. Our guide to GLP-1s for menopause weight gain goes deeper.

Does MOTS-c work for weight loss in women?

Nobody knows, because MOTS-c has not been tested for weight loss in women or men. Its evidence level is mostly animal and cell studies. The founding 2015 study reported that MOTS-c prevented diet-induced obesity and insulin resistance in mice (Lee et al., Cell Metabolism 2015, PMC), and the experiments described there used male mice. A review by the same research group summarizes its metabolic effects as coming mostly from mouse work (Lee, Kim & Cohen, Free Radic Biol Med 2016, PMC).

The study most relevant to midlife women is a 2019 experiment in ovariectomized female mice, a standard model of estrogen loss. MOTS-c treatment prevented the weight gain and insulin resistance that followed ovariectomy, reduced fat accumulation, and increased brown-fat activation (Lu et al., J Mol Med 2019). The authors called it a candidate for menopause-related metabolic dysfunction. That is a reason to study it in women, not evidence it works in women. A placebo-controlled human trial of MOTS-c itself, a phase 2a study in an estimated 120 adults aged 18 to 65 with prediabetes and overweight or obesity, began recruiting men and women in February 2026; its primary outcomes are insulin sensitivity and adverse events, not weight, and it has no results yet (ClinicalTrials.gov, NCT07505745). Our longevity site covers what the MOTS-c metabolic research shows in depth.

Does 5-Amino-1MQ work for women?

5-Amino-1MQ has no human data at all, for women or men. A search of the ClinicalTrials.gov registry on October 12, 2026 for “5-amino-1MQ” and “5-amino-1-methylquinolinium” returned no registered studies. Its evidence level is cell and mouse studies.

The fat-loss studies people quote were done in male mice. In a 2018 study, male diet-induced obese mice given the compound by injection for 11 days lost about 5% of body weight while controls gained weight, and food intake did not differ (Neelakantan et al., 2018, PMC). A 2021 study that added it to a diet switch also used male obese mice (Sampson et al., Scientific Reports 2021, PMC). The one study in females was about muscle, not fat: in 22-month-old female mice, treated sedentary mice had greater grip strength than untreated ones, and its authors disclose ties to a company developing NNMT inhibitors (Dimet-Wiley et al., Scientific Reports 2024, PMC). The Treatment Report’s 5-Amino-1MQ overview explains the chemistry and the full mouse record.

Does tesamorelin work for belly fat in women?

Tesamorelin reduces visceral belly fat, but the evidence comes almost entirely from men living with HIV. In the pivotal trial, 412 people with HIV and abdominal fat accumulation, 86% of them men, took daily tesamorelin or placebo for 26 weeks; visceral fat fell 15.2% on tesamorelin and rose 5.0% on placebo, and more people on tesamorelin withdrew because of adverse events (Falutz et al., NEJM 2007). It is a visceral-fat drug rather than a weight-loss drug, and women without HIV were not the population studied. The Treatment Report’s tesamorelin overview covers the rest of the research, and our guide to sermorelin for women covers sermorelin, the shorter growth-hormone-releasing molecule it is most often compared with.

Which peptides are best for weight loss for females?

If “best” means the most evidence in women, the answer is the approved GLP-1 drugs, tirzepatide and semaglutide. They have large randomized trials in which most participants were women, and tirzepatide has been analyzed by menopause stage, with similar-looking results across stages in an analysis its authors call exploratory (Tchang et al., 2025). MOTS-c, 5-Amino-1MQ and tesamorelin cannot be ranked for women’s weight loss, because no human weight-loss result in women exists for any of them. “Most talked about” and “best supported” are different lists.

Are peptides safe for weight loss?

The approved GLP-1 drugs have known, labeled risks that a prescriber monitors; the research compounds have no human safety record, so their safety is unknown. For Wegovy, 73% of adults in the weight trials reported gastrointestinal side effects against 47% on placebo, most often nausea (44% vs 16%), diarrhea (30% vs 16%) and vomiting (25% vs 6%), and the label carries a boxed warning because semaglutide caused thyroid C-cell tumors in rodents (Wegovy prescribing information). The Zepbound label lists nausea, diarrhea, vomiting, constipation and hair loss among its most common adverse reactions (Zepbound prescribing information).

Three label details matter specifically for women:

• Hair loss is more common in women. In pooled trials, hair loss was reported by 4% of women versus 0.9% of men on Wegovy 2.4 mg (Wegovy label), and by 7.1% of women versus 0.5% of men on Zepbound (Zepbound label). Both labels tie it to the weight reduction. Midlife hair thinning has its own options, covered in our guide to oral minoxidil for women.
• Oral contraception. The Zepbound label advises women on oral hormonal contraceptives to switch to a non-oral method, or add a barrier method, for 4 weeks after starting and after each dose increase, because delayed stomach emptying can affect the pill (Zepbound label). That is relevant in perimenopause, when pregnancy is still possible.
• Pregnancy. The Wegovy label says it may cause fetal harm and should be stopped when pregnancy is recognized (Wegovy label).

For MOTS-c and 5-Amino-1MQ there is no human side-effect data to report. “Negligible toxicity or observable adverse effects” in 9 treated mice over an 11-day test (Neelakantan et al., 2018) is not a safety profile for a woman taking something for months.

Does hormone therapy help with menopause weight?

Menopausal hormone therapy is not a weight-loss medication, but it is the most effective treatment for hot flashes and night sweats and for the genitourinary syndrome of menopause, and it helps prevent bone loss and fracture (The Menopause Society 2022 hormone therapy position statement). For most healthy women under 60 or within 10 years of menopause onset, that statement finds the benefits generally outweigh the risks, with treatment individualized and reassessed.

There is a preliminary link to weight. In a retrospective cohort of postmenopausal women on semaglutide, those also using hormone therapy lost more weight at every checkpoint: about 7% versus 5% at three months, 13% versus 9% at six months, 15% versus 10% at nine months, and 16% versus 12% at twelve months, differences that held after adjusting for confounders (Menopause, 2024). It was a small study with only 16 women in the hormone-therapy group, and the authors called for larger studies. Hormone therapy is chosen for symptoms and bone, not as a weight strategy. For a fuller comparison, see peptides and other therapies versus HRT.

Stacks and combinations women ask about

The only combination on this page with any human data is hormone therapy plus semaglutide, and that is the small retrospective signal above. No combination of MOTS-c, 5-Amino-1MQ or tesamorelin with a GLP-1 has been tested in people. Online, MOTS-c is described mainly as an “energy” peptide folded into larger routines alongside GLP peptides, NAD+ and fasting (see the community section below). The appeal is easy to see: pair an appetite drug with a compound pitched as changing how cells burn energy. The problem is that when someone takes three things at once, there is no way to tell which one did anything, good or bad.

What does weight-loss medication cost for women?

Cost varies widely, and price says nothing about evidence. Branded semaglutide and tirzepatide costs depend on insurance and the makers’ self-pay programs, which our sister site walks through in GLP-1 cost without insurance. Cheaper compounded versions are not FDA-approved, and the FDA’s temporary shortage windows for broad compounding closed in spring 2025 (FDA compounder policy); see is compounded semaglutide still legal in 2026 for the detail. Paying for a compound with only mouse data does not buy more certainty.

What women are saying about weight-loss peptides

We do not yet have a women-specific community dataset on weight-loss peptides, so this section does not characterize what women in particular report. The closest data is our Community Insights summary of 19 public posts about MOTS-c on X from July 16 to 19, 2026, which was not limited to women. These are anecdotes, not evidence:

• MOTS-c as a stack ingredient. Posters describe running MOTS-c inside wider routines alongside NAD+, GHK-Cu, GLP peptides, pre-workout, fasting and cardio, and experimenting with timing around fasting and exercise.
• Energy claims. Many posts frame MOTS-c as a mitochondrial energy peptide; some report noticeable improvements, and one poster who expected to dismiss it revisited his verdict after a month of daily use.
• Skepticism. Others call it part of a hype cycle where people chase each new peptide.

Set against the research, the conversation runs ahead of the data: the energy stories attach to a compound with no completed human treatment trial, and none of them is about weight in women. The full summary is on The Treatment Report’s MOTS-c community page. We have no community dataset yet for 5-Amino-1MQ or GLP-1s.

Other midlife questions

• Low desire. Bremelanotide (Vyleesi, often called PT-141) is FDA-approved only for acquired, generalized low sexual desire in premenopausal women (Vyleesi prescribing information, FDA); see PT-141 for women.
• Menopause symptoms. Whether peptides help with hot flashes, sleep or mood is covered in can peptides help with menopause symptoms and peptides for sleep during menopause.
• Getting care. How a menopause and weight evaluation works in practice is covered in how to get menopause care as a woman over 40.

The bottom line

“Peptides for weight loss” means very different things for women depending on which product you mean. The approved GLP-1 drugs were tested in trials where most participants were women and, in exploratory analyses, appear to work about as well after menopause as before it, with known side effects, some of them more common in women. MOTS-c has one encouraging study in a mouse model of menopause and no human weight data; 5-Amino-1MQ has male-mouse fat-loss studies and no human trials; tesamorelin was studied mostly in men with HIV. Before choosing anything, ask what species was studied, whether women were included, what was measured and for how long, and talk it through with a clinician who knows your history.

Status: 5-Amino-1MQ: Not FDA-approved; sold by some telehealth providers as a compounded prescription. MOTS-C: Not FDA-approved; sold by some telehealth providers as a compounded prescription. An FDA advisory committee reportedly voted in July 2026 to recommend allowing pharmacies to compound it; nothing has changed yet. Tesamorelin: FDA-approved only as Egrifta, for HIV-related abdominal fat; other uses are off-label. What these status terms mean.

Educational information only, not medical advice. Every efficacy and safety statement on this page is sourced to the peer-reviewed literature, FDA drug labels, trial registries, a hospital research summary or the position statement linked above; the community summary reflects public posts on X analyzed in July 2026. Updated October 12, 2026.